DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville MD 20857

FEB 2 2 2012

Ronald A. Lindsay
President/CEO
Center for Inquiry
Committee for Skeptical Inquiry
P.O. Box 741
Amherst, NY 14226-0741

Re: Docket No. FDA-2011-P-0642

Dear Mr. Lindsay:

I am writing to inform you that the Food and Drug Administration (FDA) has not yet resolved the issues raised in your citizen petition received on August 29, 2011. Your petition requests that the Agency initiate a rulemaking to require that all over-the-counter homeopathic drugs meet the standards of effectiveness applicable to non-homeopathic drugs, and that those not tested for effectiveness carry a warning label.

FDA has been unable to reach a decision on your petition because it raises complex issues requiring extensive review and analysis by Agency officials. This interim response is provided in accordance with FDA regulations on citizen petitions (21 CFR 10.30(e)(2)). We will respond to your petition as soon as we have reached a decision on your request.

Sincerely,

Jane A. Axelrad

Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research